Developer docs
API playgroundTry for free, no card

Search company profiles

MobileODT

Full company profile

uuid0002yaw

Namestring
MobileODT
Websiteurl
mobileodt.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

MobileODT is a health-tech company founded in 2012 and headquartered in Tel Aviv, Israel, that develops portable medical devices for cervical cancer screening and pre-cancerous lesion detection. Its core product is a portable, easy-to-use cervical cancer screening device built on mobile optical detection technology, designed to bring point-of-care screening to settings where traditional colposcopy infrastructure is unavailable. The company targets the women's health / cervical cancer screening vertical, with a value proposition centered on accessibility, portability, and cost-effectiveness for underserved and resource-limited healthcare environments.

The company has raised approximately $14.1M across multiple funding rounds from 2012 through 2020, with OrbiMed as a repeat lead investor and participation from mission-aligned funds such as Laerdal Million Lives Fund, Tara Health Foundation, Tristel, MedTech Innovator, and Vodafone Americas Foundation. The company is led by CEO Leon A. Boston and operates with a small team of 11-50 employees. MobileODT has been acquired by Liger Medical, an altruistic organization focused on cost-effective women's healthcare devices, and now operates as a brand/subsidiary within Liger Medical's portfolio rather than as an independent entity.

MobileODT's business model historically centered on selling or distributing portable cervical cancer screening hardware and related consumables/services to healthcare providers, NGOs, and public health programs. Pricing details are not publicly disclosed. The product is positioned as a differentiated, miniaturized alternative to traditional colposcopy, with strategic alignment to global health cervical cancer screening initiatives.

Short descriptiontext

MobileODT develops portable, AI-based optical detection devices for cervical cancer screening, targeting healthcare providers and global health programs serving women in underserved settings. The company has been acquired by Liger Medical and operates as a brand within Liger Medical's women's healthcare device portfolio.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTel Aviv, Israel
HQ citystring
Tel Aviv
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Keyword5 values
cervical cancer screening, medical imaging devices, women's health technology, portable colposcopy, AI medical diagnostics
Industry3 codes
PRIMARYHLAHABAL
Portable, Mobile & Point-of-Care Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Optical Instruments & Lenses3827
Product category
Cervical Cancer Screening Medical Devices
Social media profiles3 records
Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

MobileODT develops and sells portable, AI-enabled medical devices for the screening and detection of pre-cervical cancer in women. The product line consists of compact optical imaging hardware combined with AI-based image analysis software, enabling healthcare providers to perform point-of-care cervical cancer screening in clinics, outreach programs, and underserved settings.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Liger Medical Device Portfolio (MobileODT cervical cancer screening devices)
Partnership1 partner
1Liger Medical
Strategic tierFlagshipTypeStrategic or Co-development Partner
ligermedical.com
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Hologic is the dominant women's health diagnostics incumbent with ThinPrep cytology and Panther HPV testing platforms. It is the established standard-of-care cervical cancer screening vendor that any portable alternative must displace or complement.

TypeBroad incumbent
Description

BD's Onclarity HPV assay and women's health diagnostics portfolio compete directly for cervical screening workloads. BD's scale, regulatory reach, and channel relationships make it a primary competitive benchmark.

TypeBroad incumbent
Description

Roche's cobas HPV test is a flagship cervical cancer molecular diagnostic deployed globally. As a leading diagnostics platform, it defines the laboratory-based workflow that MobileODT's point-of-care device targets as an alternative or complement.

TypeDirect peer
Description

QIAGEN provides digene HC2 and methylation-based cervical cancer screening assays (e.g., QIAsure). It directly competes in cervical diagnostics and is commonly co-evaluated alongside portable visual screening approaches.

TypeDirect peer
Description

TruScreen is an emerging cervical cancer screening device using real-time opto-electrical tissue analysis at the point of care. It is one of the closest direct peers to MobileODT's portable visual AI screening offering.

TypeDirect peer
Description

DYSIS Medical builds DYSIS colposcopes with computer-aided mapping for cervical examination. It competes head-to-head in the portable colposcopy/visual screening segment that MobileODT addresses.

TypeBroad incumbent
Description

CooperSurgical is a leading women's health medical device company spanning ART, obstetrics, and cervical screening/colposcopy products. It is a broad incumbent competing across the women's health device landscape MobileODT targets.

TypeBroad incumbent
Description

Revvity provides clinical diagnostics and screening assays, including in oncology and women's health. As a broad diagnostics incumbent, it competes for the same cervical and women's health screening budgets as MobileODT.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MobileODT

Cervical Cancer Screening Medical Devicesmobileodt.com

MobileODT develops portable, AI-based optical detection devices for cervical cancer screening, targeting healthcare providers and global health programs serving women in underserved settings. The company has been acquired by Liger Medical and operates as a brand within Liger Medical's women's healthcare device portfolio.

What MobileODT does

MobileODT is a health-tech company founded in 2012 and headquartered in Tel Aviv, Israel, that develops portable medical devices for cervical cancer screening and pre-cancerous lesion detection. Its core product is a portable, easy-to-use cervical cancer screening device built on mobile optical detection technology, designed to bring point-of-care screening to settings where traditional colposcopy infrastructure is unavailable. The company targets the women's health / cervical cancer screening vertical, with a value proposition centered on accessibility, portability, and cost-effectiveness for underserved and resource-limited healthcare environments.

The company has raised approximately $14.1M across multiple funding rounds from 2012 through 2020, with OrbiMed as a repeat lead investor and participation from mission-aligned funds such as Laerdal Million Lives Fund, Tara Health Foundation, Tristel, MedTech Innovator, and Vodafone Americas Foundation. The company is led by CEO Leon A. Boston and operates with a small team of 11-50 employees. MobileODT has been acquired by Liger Medical, an altruistic organization focused on cost-effective women's healthcare devices, and now operates as a brand/subsidiary within Liger Medical's portfolio rather than as an independent entity.

MobileODT's business model historically centered on selling or distributing portable cervical cancer screening hardware and related consumables/services to healthcare providers, NGOs, and public health programs. Pricing details are not publicly disclosed. The product is positioned as a differentiated, miniaturized alternative to traditional colposcopy, with strategic alignment to global health cervical cancer screening initiatives.

MobileODT firmographics

Firmographics
Name
MobileODT
Website
https://mobileodt.com
Company type
Private
Founded year
2012
Operating status
Acquired
Headcount range
1–10 employees
Short description
MobileODT develops portable, AI-based optical detection devices for cervical cancer screening, targeting healthcare providers and global health programs serving women in underserved settings. The company has been acquired by Liger Medical and operates as a brand within Liger Medical's women's healthcare device portfolio.
Ownership category
akta.pro rank

MobileODT industry classification

Industry
Product category
Cervical Cancer Screening Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Optical Instruments & Lenses (3827)
akta.pro industry
PRIMARYHLAHABAL
Portable, Mobile & Point-of-Care Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Cervical cancer screening
  • Medical imaging devices
  • Women's health technology
  • Portable colposcopy
  • AI medical diagnostics

Where MobileODT is headquartered

Location

Headquarters

HQ city
Tel Aviv
HQ country
Israel
HQ region
Middle East

Markets served

MobileODT business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

MobileODT product offering

Product offering

Core offering

MobileODT develops and sells portable, AI-enabled medical devices for the screening and detection of pre-cervical cancer in women. The product line consists of compact optical imaging hardware combined with AI-based image analysis software, enabling healthcare providers to perform point-of-care cervical cancer screening in clinics, outreach programs, and underserved settings.

Differentiator

Problem solved

Functional benefit

Products and services

  • Liger Medical Device Portfolio (MobileODT cervical cancer screening devices)

Companies that use MobileODT

Customer profile

Segments1 record

Ideal customer profiles1 record

MobileODT technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

MobileODT partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Liger MedicalflagshipStrategic or Co-development Partner

Recent moves3 records

Expansion highlights3 records

MobileODT competitors and assessment

Company assessment

Broad incumbents

  • Hologic: Hologic is the dominant women's health diagnostics incumbent with ThinPrep cytology and Panther HPV testing platforms. It is the established standard-of-care cervical cancer screening vendor that any portable alternative must displace or complement.
  • Becton, Dickinson and Company (BD): BD's Onclarity HPV assay and women's health diagnostics portfolio compete directly for cervical screening workloads. BD's scale, regulatory reach, and channel relationships make it a primary competitive benchmark.
  • Roche Diagnostics: Roche's cobas HPV test is a flagship cervical cancer molecular diagnostic deployed globally. As a leading diagnostics platform, it defines the laboratory-based workflow that MobileODT's point-of-care device targets as an alternative or complement.
  • CooperSurgical: CooperSurgical is a leading women's health medical device company spanning ART, obstetrics, and cervical screening/colposcopy products. It is a broad incumbent competing across the women's health device landscape MobileODT targets.
  • Revvity (formerly PerkinElmer): Revvity provides clinical diagnostics and screening assays, including in oncology and women's health. As a broad diagnostics incumbent, it competes for the same cervical and women's health screening budgets as MobileODT.

Direct peers

  • QIAGEN: QIAGEN provides digene HC2 and methylation-based cervical cancer screening assays (e.g., QIAsure). It directly competes in cervical diagnostics and is commonly co-evaluated alongside portable visual screening approaches.
  • TruScreen: TruScreen is an emerging cervical cancer screening device using real-time opto-electrical tissue analysis at the point of care. It is one of the closest direct peers to MobileODT's portable visual AI screening offering.
  • DYSIS Medical: DYSIS Medical builds DYSIS colposcopes with computer-aided mapping for cervical examination. It competes head-to-head in the portable colposcopy/visual screening segment that MobileODT addresses.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

MobileODT social profiles

Digital presence

MobileODT financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MobileODT leadership team

Management profile

Number of profiles

Profiles1 record

MobileODT funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MobileODT M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MobileODT

What does MobileODT do?

MobileODT develops and sells portable, AI-enabled medical devices for the screening and detection of pre-cervical cancer in women. The product line consists of compact optical imaging hardware combined with AI-based image analysis software, enabling healthcare providers to perform point-of-care cervical cancer screening in clinics, outreach programs, and underserved settings.

Is MobileODT a public or private company?

MobileODT is a private company. It is classified as corporate owned and is currently acquired.

When was MobileODT founded?

MobileODT was founded in 2012. It employs 1 to 10 people.

Where is MobileODT based?

MobileODT is headquartered in Tel Aviv, Israel, in the Middle East region.

Who are MobileODT's main competitors?

Broad incumbents on record are Hologic, Becton, Dickinson and Company (BD), Roche Diagnostics, CooperSurgical and Revvity (formerly PerkinElmer). Direct peers are QIAGEN, TruScreen and DYSIS Medical.

Does MobileODT have an API?

No public API is recorded for MobileODT.

What industry is MobileODT in?

MobileODT's product category is Cervical Cancer Screening Medical Devices. Its primary akta.pro industry code is HLAHABAL, Portable, Mobile & Point-of-Care Imaging Systems, with a secondary code of HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireMobileODT Recognized for Imaging Technology Innovation in 2022 MedTech Breakthrough Awards ProgramMobileODT, an Israeli FemTech company, was awarded the "Best New Imaging Technology Solution" in the 2022 MedTech Breakthrough Awards program for its EVA System, which uses AI-powered cervical cancer screening technology capable of returning results in under 60 seconds. The award recognizes the company as the only entity worldwide with AI capability for cervical cancer screening that can perform screening at scale, addressing a critical gap given that over 300,000 women die from cervical cancer annually. The recognition from the independent market intelligence organization validates the company's strategic positioning ahead of supporting the World Health Organization's goal to eliminate cervical cancer by 2030.Forbes IndiaIs 'Femtech' the next big thing in health care?The femtech industry generated $820.6 million in global revenue and $592 million in venture capital in 2019, with women spending $500 billion annually on medical expenses. The market is expected to reach $1.1 billion by 2024, with startups like MobileODT and Lattice Medical developing cervical cancer screening and breast regeneration technologies.AiThorityIsraeli FemTech Company MobileODT, Engaged in Large Scale Government Cervical Cancer Screening ProjecMobileODT's Visual Check AI technology is supporting a government cervical cancer screening project in the Dominican Republic, where 9,000 women were screened in three months. The program will expand to cover 50,000 women over the next six months. The company is in a funding round to expand its AI-based screening capabilities.PR NewswireIsraeli FemTech Company MobileODT, Engaged in Large Scale Government Cervical Cancer Screening ProjectMobileODT, an Israeli FemTech company, announced that its EVA Visual Check AI technology is supporting a large-scale government cervical cancer screening project initiated by the Dominican Republic Ministry of Health, with 9,000 women screened in the first three months. Due to the project's initial success, the program is being expanded to cover an additional 50,000 women over the next six months, with the AI technology enabling non-specialists to predict cervical cancer diagnoses at the point of care. The company, which has raised $26 million to date and is currently in a funding round, claims to be the only company in the world with AI capability in cervical cancer screening.PR NewswireFemTech Company MobileODT awarded prestigious National Cancer Institute (NCI) SBIR grant of $2.3 millionMobileODT, a Tel Aviv-based FemTech company, has been awarded a $2.3 million Small Business Innovation Research grant from the U.S. National Cancer Institute to conduct a large-scale clinical trial validating its AI-based cervical cancer screening technology.Business Up NorthHITRANS chooses Mobilleo to power its GO-HI rural MaaS project in ScotlandHITRANS selected Fleetondemand's Mobilleo platform to power its GO-HI rural MaaS pilot in Scotland, launching in March 2021. The project, funded by EU and Scottish government funds, integrates transport partners including ScotRail and Stagecoach. It aims to improve accessibility and reduce car reliance in the Highlands and Islands.FinSMEsMobileODT Closes $4M in Series C RoundMobileODT, a Tel Aviv-based cervical cancer screening developer, closed a $4M Series C round led by OrbiMed Israel Partners, bringing total funding to $26M. The company will use the funds to develop AI clinical decision support for cervical cancer evaluation at the point of care.PR NewswireMobileODT completed $4 million series round CMobileODT, an Israeli medical technology company developing the EVA System for cervical cancer screening, announced the completion of a $4 million Series C fundraising round led by OrbiMed Israel Partners with participation from Tristel, Tara Health, and Laerdal. The company has now raised a total of $26 million to date, which will fund the development and launch of its AI-powered VisualCheck technology for automated cervical cancer evaluation at the point of care. The AI technology recently completed initial validation showing high agreement rates with expert evaluations and is planned for release later this year.PR NewswireProspective Pilot Shows AI to Have Higher Accuracy in Detecting Cervical Cancer Than Lab TestsA prospective pilot study completed in South Korea tested MobileODT's AI-powered CDS algorithm on the EVA System against traditional Pap cytology in 212 patients for cervical cancer detection. The AI system demonstrated higher accuracy than Pap cytology while delivering results within one minute at point-of-care, compared to the 1-3 days required for laboratory-based Pap testing. MobileODT, in partnership with South Korean medical equipment company Laonz, is positioning this as the first real-world deployment of AVE AI technology for cervical cancer screening, with results to be presented at the ASCCP Annual Scientific Meeting in Atlanta.The Jerusalem PostHillel Fuld’s Tech Corner - MobileODT: Saving Lives with ComfortThe EVA system uses augmented intelligence to detect cervical cancer more efficiently than a Pap test. When caught early, the disease is treatable with a point-of-care therapy that takes less than 30 minutes and costs under $28.